Table 2 Comparison of basic information between this NMA and other 2 studies

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study | Database | Retrieval time | Disease | Intervention VS control | Outcome | GRADE evaluation |
| Liu S2018[19] | PubMed,  Cochrane Library,  Embase,  CNKI,  Wanfang Database,  CBM. | inception to June 2016 | acute cerebral  infarction(ACI) | 1.CHIs①+AADN regimen VS AADN regimen  2. CHI a+AADN regimen VS CHI b+AADN regimen | 1.the markedly effective rate  2.improvement of  neurological impairment  3.activities of daily living function  4.death from all causes within the treatment and during the entire follow-up period | no |
| Xiang Y2017[20] | PubMed,  Cochrane Library,  Embase,  CNKI,  Wanfang Database,  CBM,  Chongqing VIP. | Inception to June 2016 | Stroke | 1.CMIs②+conventional treatment VS conventional treatment  2. CMIs +conventional treatment VS placebo  3.CMIs+ conventional treatment VS other CMIs  4.CMIs+ conventional treatment VS western medicine | 1. the markedly effective rate  2. neurological deficit score  3. daily activity ability score  4. adverse event incidence  5.mortality  6.cerebral hematoma changes  7.safety evaluation of adverse/reactive events  8.disability rate  9.quality of life. | no |
| the current NMA | PubMed,  Cochrane Library,  Embase,  CNKI,  Wanfang Database,  Sinomed ,  Chongqing VIP. | inception to July 2018 | acute cerebral  infarction(ACI) | 1.CMI③ a + conventional treatment VS CMI b + conventional treatment  2.CMI + conventional treatment VS conventional treatment. | 1. mortality  2. the rate of cerebrovascular event including recurrence event  3.improvement of neurological impairment  4.activities of daily living function  5.adverse drug events  6. the markedly effective rate | yes |

PS: 1.AADN inclide: aspirin + anticoagulants + dehydrant + neuroprotectant.

2. CHIs① include: Ligustrazine injection ,Xueshuantong injection, Xuesaitong injection, Shuxuening injection, Dengzhanxixin injection, Dengzhanhuasu injection, Shuxuetong injection, Danhong injection, Fufangdanshen injection, Ginkgo Leaf Extract and Dipyridamole Injection, Mailuoning injection, Honghuahuangsesu injection, Shenxiong glucose injection, salviae miltiorrhizae ,ligustrazine hydrochloride injection, Danshen injection.

3. CMIs② include: Fufangdanshen injection, Danhong injection, Ginkgo Leaf Extract and Dipyridamole Injection, Dengzhanxixin injection, Dengzhanhuasu injection, Shuxuetong injection, salviae miltiorrhizae ,ligustrazine hydrochloride injection, Shuxuening injection, Mailuoning injection,Gegensu injection, Kudiezi injection, Danshen injection,Danshen polyphenolate injection, Xueshuantong injection, Xuesaitong injection,Xinding injection, Extract of Ginkgo Biloba Leaves Injection.

4. CMI③ include: Shuxuening injection, Xiangdan injection,Shuxuetong injection, Kudiezi injection,Xuesaitong injection, Xueshuantong injection, Dengzhanhuasu injection, Danhong injection, Dengzhanxixin injection,Danshen injection, Mailuoning injection,Xingnaojing injection

5. conventional treatment include: thrombolytic therapy, anticoagulant therapy, antiplatelet aggregation therapy and some other symptomatic supportive treatments, such as control of blood pressure and adjustment of blood lipids.